Immunization with the heptavalent pneumococcal conjugate vaccine in Bangladeshi infants and effects of zinc supplementation

Saskia J.M. Osendarp; Hari Prabhakar; George J. Fuchs; Joop M.A. van Raaij; Hasan Mahmud; Fahmida Tofail; Mathuram Santosham; Robert E. Black

doi:10.1016/j.vaccine.2007.01.001

Immunization with the heptavalent pneumococcal conjugate vaccine in Bangladeshi infants and effects of zinc supplementation

Saskia J.M. Osendarp, Hari Prabhakar, George J. Fuchs, Joop M.A. van Raaij, Hasan Mahmud, Fahmida Tofail, Mathuram Santosham, Robert E. Black

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Background: Zinc deficiency is known to impair immunologic functions. However, the effect of zinc supplementation on immune response to polysaccharide vaccines is not known. Objective: To determine the immunogenicity of the heptavalent Pneumococcal protein conjugate (PNC) vaccine in poor Bangladeshi infants and to assess the effect of zinc supplementation on immune response to the PNC vaccine. Design: We immunized a sub-cohort of 241 infants who had previously received three doses of a Hib conjugate vaccine with three doses of the heptavalent PNC vaccine at 4 weeks intervals beginning at 18 ± 1 weeks of age. The infants were supplemented with daily 5 mg zinc or placebo from 4 to 33 weeks of age. Response to each of the seven PNC serotypes were assessed at 4, 24 and 33 weeks of age. Results: After three doses of PNC, at 29 weeks of age, geometric mean titres for the pneumococcal serotypes ranged from 3.68 to 13.34 μg/ml. Titres were significantly higher for infants who had received PNC compared to infants who had only received DTP-Hib. Zinc supplementation resulted in higher titres for serotype 9V (4.09 μg/ml; [95% CI: 3.27; 5.10] and 3.33 μg/ml; [95% CI: 2.79; 3.96] for zinc and placebo group, respectively; p < 0.05) after three doses but had no effect on other serotypes. Conclusions: A heptavalent PNC vaccine proved to be safe and immunogenic in Bangladeshi infants. Zinc supplementation enhanced the immune response to only one of the serotypes (9V). However, there was no effect on other serotypes.

Original language	English
Pages (from-to)	3347-3354
Number of pages	8
Journal	Vaccine
Volume	25
Issue number	17
DOIs	https://doi.org/10.1016/j.vaccine.2007.01.001
State	Published - Apr 30 2007

Bibliographical note

Funding Information:
We greatly appreciate the sincere collaboration of all mothers and their infants involved in this study and the work of our dedicated field staff. Gary Darmstadt and David Sack were kind enough to hand carry samples to the US for analysis. This study was conducted at ICDDR, B: Centre for Health and Population Research with the support of grants from the Johns Hopkins Family Health and Survival Cooperative Agreement with USAID, the Royal Netherlands Government (Activity number: RISC, BD009602) and from Wyeth Lederle Vaccines, NY, USA. ICDDR, B acknowledges with gratitude the commitments of USAID, the Royal Netherlands Government and Wyeth Lederle Vaccines to the Centre's research efforts.

Keywords

Developing countries
Immune response
Infants
Pneumococcal conjugate vaccine
Zinc supplementation

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2007.01.001

Cite this

@article{b74c617169084acfb5ac9097f8adabe4,

title = "Immunization with the heptavalent pneumococcal conjugate vaccine in Bangladeshi infants and effects of zinc supplementation",

abstract = "Background: Zinc deficiency is known to impair immunologic functions. However, the effect of zinc supplementation on immune response to polysaccharide vaccines is not known. Objective: To determine the immunogenicity of the heptavalent Pneumococcal protein conjugate (PNC) vaccine in poor Bangladeshi infants and to assess the effect of zinc supplementation on immune response to the PNC vaccine. Design: We immunized a sub-cohort of 241 infants who had previously received three doses of a Hib conjugate vaccine with three doses of the heptavalent PNC vaccine at 4 weeks intervals beginning at 18 ± 1 weeks of age. The infants were supplemented with daily 5 mg zinc or placebo from 4 to 33 weeks of age. Response to each of the seven PNC serotypes were assessed at 4, 24 and 33 weeks of age. Results: After three doses of PNC, at 29 weeks of age, geometric mean titres for the pneumococcal serotypes ranged from 3.68 to 13.34 μg/ml. Titres were significantly higher for infants who had received PNC compared to infants who had only received DTP-Hib. Zinc supplementation resulted in higher titres for serotype 9V (4.09 μg/ml; [95% CI: 3.27; 5.10] and 3.33 μg/ml; [95% CI: 2.79; 3.96] for zinc and placebo group, respectively; p < 0.05) after three doses but had no effect on other serotypes. Conclusions: A heptavalent PNC vaccine proved to be safe and immunogenic in Bangladeshi infants. Zinc supplementation enhanced the immune response to only one of the serotypes (9V). However, there was no effect on other serotypes.",

keywords = "Developing countries, Immune response, Infants, Pneumococcal conjugate vaccine, Zinc supplementation",

author = "Osendarp, {Saskia J.M.} and Hari Prabhakar and Fuchs, {George J.} and {van Raaij}, {Joop M.A.} and Hasan Mahmud and Fahmida Tofail and Mathuram Santosham and Black, {Robert E.}",

note = "Funding Information: We greatly appreciate the sincere collaboration of all mothers and their infants involved in this study and the work of our dedicated field staff. Gary Darmstadt and David Sack were kind enough to hand carry samples to the US for analysis. This study was conducted at ICDDR, B: Centre for Health and Population Research with the support of grants from the Johns Hopkins Family Health and Survival Cooperative Agreement with USAID, the Royal Netherlands Government (Activity number: RISC, BD009602) and from Wyeth Lederle Vaccines, NY, USA. ICDDR, B acknowledges with gratitude the commitments of USAID, the Royal Netherlands Government and Wyeth Lederle Vaccines to the Centre's research efforts.",

year = "2007",

month = apr,

day = "30",

doi = "10.1016/j.vaccine.2007.01.001",

language = "English",

volume = "25",

pages = "3347--3354",

number = "17",

}

TY - JOUR

T1 - Immunization with the heptavalent pneumococcal conjugate vaccine in Bangladeshi infants and effects of zinc supplementation

AU - Osendarp, Saskia J.M.

AU - Prabhakar, Hari

AU - Fuchs, George J.

AU - van Raaij, Joop M.A.

AU - Mahmud, Hasan

AU - Tofail, Fahmida

AU - Santosham, Mathuram

AU - Black, Robert E.

N1 - Funding Information: We greatly appreciate the sincere collaboration of all mothers and their infants involved in this study and the work of our dedicated field staff. Gary Darmstadt and David Sack were kind enough to hand carry samples to the US for analysis. This study was conducted at ICDDR, B: Centre for Health and Population Research with the support of grants from the Johns Hopkins Family Health and Survival Cooperative Agreement with USAID, the Royal Netherlands Government (Activity number: RISC, BD009602) and from Wyeth Lederle Vaccines, NY, USA. ICDDR, B acknowledges with gratitude the commitments of USAID, the Royal Netherlands Government and Wyeth Lederle Vaccines to the Centre's research efforts.

PY - 2007/4/30

Y1 - 2007/4/30

N2 - Background: Zinc deficiency is known to impair immunologic functions. However, the effect of zinc supplementation on immune response to polysaccharide vaccines is not known. Objective: To determine the immunogenicity of the heptavalent Pneumococcal protein conjugate (PNC) vaccine in poor Bangladeshi infants and to assess the effect of zinc supplementation on immune response to the PNC vaccine. Design: We immunized a sub-cohort of 241 infants who had previously received three doses of a Hib conjugate vaccine with three doses of the heptavalent PNC vaccine at 4 weeks intervals beginning at 18 ± 1 weeks of age. The infants were supplemented with daily 5 mg zinc or placebo from 4 to 33 weeks of age. Response to each of the seven PNC serotypes were assessed at 4, 24 and 33 weeks of age. Results: After three doses of PNC, at 29 weeks of age, geometric mean titres for the pneumococcal serotypes ranged from 3.68 to 13.34 μg/ml. Titres were significantly higher for infants who had received PNC compared to infants who had only received DTP-Hib. Zinc supplementation resulted in higher titres for serotype 9V (4.09 μg/ml; [95% CI: 3.27; 5.10] and 3.33 μg/ml; [95% CI: 2.79; 3.96] for zinc and placebo group, respectively; p < 0.05) after three doses but had no effect on other serotypes. Conclusions: A heptavalent PNC vaccine proved to be safe and immunogenic in Bangladeshi infants. Zinc supplementation enhanced the immune response to only one of the serotypes (9V). However, there was no effect on other serotypes.

AB - Background: Zinc deficiency is known to impair immunologic functions. However, the effect of zinc supplementation on immune response to polysaccharide vaccines is not known. Objective: To determine the immunogenicity of the heptavalent Pneumococcal protein conjugate (PNC) vaccine in poor Bangladeshi infants and to assess the effect of zinc supplementation on immune response to the PNC vaccine. Design: We immunized a sub-cohort of 241 infants who had previously received three doses of a Hib conjugate vaccine with three doses of the heptavalent PNC vaccine at 4 weeks intervals beginning at 18 ± 1 weeks of age. The infants were supplemented with daily 5 mg zinc or placebo from 4 to 33 weeks of age. Response to each of the seven PNC serotypes were assessed at 4, 24 and 33 weeks of age. Results: After three doses of PNC, at 29 weeks of age, geometric mean titres for the pneumococcal serotypes ranged from 3.68 to 13.34 μg/ml. Titres were significantly higher for infants who had received PNC compared to infants who had only received DTP-Hib. Zinc supplementation resulted in higher titres for serotype 9V (4.09 μg/ml; [95% CI: 3.27; 5.10] and 3.33 μg/ml; [95% CI: 2.79; 3.96] for zinc and placebo group, respectively; p < 0.05) after three doses but had no effect on other serotypes. Conclusions: A heptavalent PNC vaccine proved to be safe and immunogenic in Bangladeshi infants. Zinc supplementation enhanced the immune response to only one of the serotypes (9V). However, there was no effect on other serotypes.

KW - Developing countries

KW - Immune response

KW - Infants

KW - Pneumococcal conjugate vaccine

KW - Zinc supplementation

UR - http://www.scopus.com/inward/record.url?scp=34047137279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047137279&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2007.01.001

DO - 10.1016/j.vaccine.2007.01.001

M3 - Article

C2 - 17289221

AN - SCOPUS:34047137279

SN - 0264-410X

VL - 25

SP - 3347

EP - 3354

JO - Vaccine

JF - Vaccine

IS - 17

ER -

Immunization with the heptavalent pneumococcal conjugate vaccine in Bangladeshi infants and effects of zinc supplementation

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this